Protein / target

Lactotransferrin

Encoded byLTFP02788Homo sapiensSwiss-Prot

UniProt: P02788 Ensembl: ENSG00000012223 HGNC: HGNC:6720 NCBI Gene: 4057

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Protein serine/threonine kinase activator

Strongest disease association

Schizophrenia

Via encoding gene LTF · Genetic evidence · score 0.40

Research activity

Emerging research

4 papers · latest 2021

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate

Subcellular location

SecretedCytoplasmic granuleCytoplasmNucleus

Domains and Gene Ontology detail (52)

Domains & features

Transferrin-like 1Transferrin-like 2

Gene Ontology

Ccell surface
Ccytoplasm
Cearly endosome
Cextracellular exosome
Cextracellular region
Cextracellular space
Cnucleus
Cphagocytic vesicle lumen
Cplasma membrane
Cprotein-containing complex
Crecycling endosome
Csecretory granule

710 aa · 78 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGOProteolysisGO

View supporting evidence

Immune signalling

·antimicrobial humoral immune response mediated by antimicrobial peptide
·humoral immune response
·innate immune response in mucosa
·regulation of cytokine production

Proteolysis

·serine-type endopeptidase activity
·proteolysis

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene LTF

Gene-level evidence surfaced through the gene LTFthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Schizophrenia

0.42Limited support

Genetic evidence dominant · Open Targets 0.25

Inflammatory Bowel Diseases

0.42Limited support

Genetic evidence dominant · Open Targets 0.23

Tuberculosis

0.38Preliminary

Pathway evidence dominant · Open Targets 0.52 · no direct causal or clinical evidence

Immunoglobulin Light-chain Amyloidosis

0.32Preliminary

Pathway evidence dominant · Open Targets 0.47 · no direct causal or clinical evidence

Alzheimer's Disease

0.23Preliminary

Literature evidence dominant · Open Targets 0.21 · no direct causal or clinical evidence

View evidence synthesis (5)

SchizophreniaLimited support

0.42

agreement 0.29–0.56

Genetic91%Literature9%

Open Targets aggregate 0.25 · 2 independent evidence families

Inflammatory Bowel DiseasesLimited support

0.42

agreement 0.28–0.56

Genetic77%Literature23%

Open Targets aggregate 0.23 · 2 independent evidence families

TuberculosisPreliminary

0.38

agreement 0.23–0.53

Pathway82%Literature17%RNA expression1%

Open Targets aggregate 0.52 · 3 independent evidence families · no direct causal or clinical evidence

Immunoglobulin Light-chain AmyloidosisPreliminary

0.32

agreement 0.14–0.50

Pathway92%Literature8%

Open Targets aggregate 0.47 · 2 independent evidence families · no direct causal or clinical evidence

Alzheimer's DiseasePreliminary

0.23

agreement 0.09–0.38

Literature50%Pathway49%RNA expression2%

Open Targets aggregate 0.21 · 3 independent evidence families · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Tuberculosis0.52

Immunoglobulin Light-chain Amyloidosis0.47

Schizophrenia0.25

Inflammatory Bowel Diseases0.23

Alzheimer's Disease0.21

Parkinson's Disease0.19

Neurodegenerative Diseases0.19

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)

SM · Structure with LigandSM · High-Quality PocketAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Database Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.